\-\ Texto\\:\\ \ \(0\)\
\-\ alert\\ and\\ oriented\\ x\\ 3\\.\\ left\\ homonymous\\ hemianopsia\\ with\\ macular\\ sparing\\,\\ horizontal\\ and\\ vertical\\ nystagmus\\,\\ normal\\ dtrs\\ bilat\\,\\ severe\\ upper\\ extremity\\ dysmetria\\ on\\ right\\,\\ abnormal\\ romberg\\.\\ unable\\ to\\ do\\ tandem\\ gait\\,\\ and\\ bumps\\ into\\ objects\\ on\\ left\\.\\ \\ lp\\:\\ positive\\ 14\\-3\\-3\\ protein\\,\\ increased\\ protein\\,\\ rbcs\\,\\ and\\ polysegs\\.\\ elevated\\ ast\\/alt\\.\\ elevated\\ thyroid\\ auto\\-antibodies\ \(0\)\
\-\ pt\\ was\\ admitted\\ to\\ the\\ neurology\\ ward\\,\\ and\\ a\\ full\\ neurological\\ work\\-up\\ was\\ started\\.\\ paraneoplastic\\/neoplastic\\ etiologies\\ were\\ excluded\\ due\\ to\\ rapid\\ progression\\ and\\ as\\ a\\ result\\ of\\ test\\ results\\.\\ pt\\â\\€\\™s\\ mental\\ status\\ continued\\ to\\ decline\\,\\ and\\ he\\ was\\ started\\ on\\ high\\ dose\\ steroids\\ course\\ for\\ possible\\ hashimoto\\â\\€\\™s\\ encephalopathy\\,\\ after\\ labs\\ showed\\ increased\\ auto\\-antibodies\\ to\\ the\\ thyroid\\.\\ transitioned\\ to\\ prednisone\\ 80mg\\ qd\\,\\ and\\ started\\ on\\ serroquel\\ and\\ geodon\\ for\\ agitation\\ and\\ sundowning\\.\\ \\ condition\\ continued\\ to\\ worsen\\ with\\ difficulty\\ protecting\\ airway\\ and\\ he\\ was\\ intubated\\ and\\ transferred\\ to\\ micu\\.\\ pt\\ was\\ placed\\ on\\ ventilator\\ and\\ found\\ to\\ have\\ a\\ retroperitoneal\\ bleed\\.\\ pt\\ had\\ brain\\ biopsy\\ that\\ confirmed\\ cjd\\.\\ after\\ consultation\\ with\\ the\\ family\\ he\\ was\\ extubated\\ and\\ moved\\ to\\ a\\ general\\ medicine\\ ward\\.\\ he\\ expired\\ the\\ following\\ week\\.\ \(0\)\
\-\ dwi\\ abnormalities\\ in\\ right\\ occipital\\ lobe\\/post\\ temporal\\ cortex\\ w\\/o\\ corresponding\\ t2\\ changes\\.\\ \\ \ \(0\)\
\-\ pet\\:\\ abnormal\\ hypometabolism\\ r\\ cerebrum\\ and\\ r\\ cerebellum\\.\ \(0\)\
\-\ creutzfeldt\\-jakob\\ disease\ \(0\)\
\-\ alzheimer\\ disease\\,\\ frontal\\ and\\ temporal\\ dementia\\,\\ hiv\\ and\\ hsv\\ encephalitis\\,\\ hydrocephalus\\,\\ metabolic\\ disorders\\,\\ multi\\-infarct\\ dementia\\,\\ diffuse\\ lewey\\ body\\ disease\\,\\ hashimoto\\ encephalopathy\\.\ \(0\)\
\-\ 63\\ y\\/o\\ male\\ with\\ history\\ of\\ nhl\\,\\ and\\ three\\ weeks\\ of\\ decreasing\\ visual\\ acuity\\,\\ gait\\ ataxia\\,\\ and\\ poor\\ coordination\\ of\\ left\\ arm\\,\\ that\\ is\\ worse\\ in\\ am\\ and\\ improving\\ during\\ the\\ course\\ of\\ day\\.\\ new\\ onset\\ of\\ personality\\ changes\\ and\\ mood\\ lability\\.\ \(0\)\
\-\ creutzfeldt\\-jacob\\ disease\\ \\(cjd\\)\\ is\\ a\\ transmissible\\ neurodegenerative\\ spongiform\\ encephalopathy\\,\\ that\\ is\\ progressive\\ and\\ ultimately\\ fatal\\,\\ with\\ no\\ effective\\ treatment\\ at\\ the\\ present\\ time\\.\\ it\\ is\\ classified\\ as\\ a\\ prion\\ disease\\,\\ which\\ is\\ an\\ abnormal\\ conformation\\ of\\ a\\ host\\ glycoprotein\\,\\ that\\ replicates\\ in\\ a\\ self\\-perpetuating\\ cycle\\ of\\ abnormal\\ proteins\\ and\\ amyloid\\ plaques\\.\\ cjd\\ has\\ a\\ long\\ incubation\\ period\\,\\ with\\ most\\ cases\\ presenting\\ in\\ the\\ sixth\\ or\\ seventh\\ decade\\ of\\ life\\.\\ cjd\\ has\\ a\\ mean\\ onset\\ of\\ 62\\ years\\,\\ with\\ reports\\ of\\ cases\\ ranging\\ from\\ 17\\ to\\ 83\\ years\\ of\\ age\\.\\ the\\ incidence\\ is\\ approximately\\ 1\\ case\\ per\\ million\\ internationally\\ and\\ in\\ the\\ united\\ states\\,\\ with\\ some\\ libyan\\ jewish\\ populations\\ and\\ a\\ few\\ populations\\ in\\ rural\\ areas\\ of\\ slovakia\\,\\ having\\ 60\\-100\\ times\\ this\\ rate\\ of\\ familial\\ cjd\\.\\ \ \(0\)\
\-\ there\\ are\\ three\\ classifications\\ of\\ cjd\\:\\ sporadic\\ \\(spontaneous\\ mutation\\)\\,\\ variant\\ \\(infectious\\)\\,\\ and\\ familial\\.\\ familial\\ cjd\\ accounts\\ for\\ about\\ 10\\%\\ of\\ all\\ cases\\,\\ and\\ is\\ inherited\\ in\\ an\\ autosomal\\ dominant\\ pattern\\.\\ \\ the\\ mean\\ duration\\ after\\ symptoms\\ present\\ is\\ 8\\ months\\ for\\ the\\ sporadic\\ form\\,\\ 16\\ months\\ for\\ variant\\,\\ and\\ 26\\ months\\ for\\ familial\\ form\\.\\ \ \(0\)\
\-\ cjd\\ is\\ characterized\\ by\\ a\\ rapidly\\ progressive\\ cognitive\\ imparement\\,\\ behavorial\\ abnormalities\\,\\ myoclonic\\ jerks\\,\\ higher\\ cortical\\ dysfunction\\ and\\ visual\\ cortical\\ abnormalities\\,\\ cerebellar\\ dysfunction\\,\\ and\\ pyramidal\\ and\\ extrapyramidal\\ signs\\.\\ these\\ signs\\ and\\ symptoms\\ steadily\\ increase\\,\\ with\\ death\\ primarily\\ occurring\\ secondary\\ to\\ bronchopneumonia\\,\\ due\\ to\\ overall\\ disability\\ and\\ a\\ bed\\-ridden\\ state\\.\ \(0\)\
\-\ testing\\ for\\ cjd\\ is\\ difficult\\ at\\ best\\,\\ and\\ in\\ its\\ early\\ stages\\ can\\ present\\ like\\ many\\ different\\ disease\\ processes\\,\\ with\\ a\\ definitive\\ diagnosis\\ being\\ accomplished\\ only\\ after\\ a\\ biopsy\\ of\\ brain\\ tissue\\.\\ sixty\\ percent\\ of\\ patients\\ show\\ characteristic\\ eeg\\ changes\\ of\\ periodic\\ sharp\\ wave\\ complexes\\ \\(pswcs\\)\\ on\\ a\\ slow\\ and\\ low\\-voltage\\ background\\.\\ \\ however\\,\\ eeg\\ has\\ a\\ low\\ specificity\\ and\\ a\\ sensitivity\\ of\\ only\\ 50\\.0\\%\\.\\ testing\\ for\\ brain\\ specific\\ proteins\\ such\\ as\\ the\\ 14\\-3\\-3\\ protein\\ and\\ the\\ neuron\\-specific\\ enolase\\ also\\ supports\\ a\\ diagnoses\\ of\\ cjd\\,\\ but\\ even\\ though\\ they\\ are\\ more\\ specific\\ than\\ eeg\\,\\ they\\ have\\ a\\ sensitivity\\ of\\ 84\\.0\\%\\ and\ \(0\)\
\-\ 73\\.3\\%\\ respectfully\\.\ \(1\)\
\-\ pet\\ scanning\\ may\\ show\\ regional\\ hypometabolism\\ of\\ glucose\\.\ \(0\)\
\-\ the\\ most\\ sensitive\\ test\\ to\\ date\\ is\\ the\\ mri\\ diffusion\\ weighted\\ images\\ \\(dwi\\)\\,\\ which\\ has\\ a\\ sensitivity\\ and\\ specificity\\ of\\ 92\\.3\\%\\ and\\ 93\\.8\\ respectfully\\.\\ dwi\\ is\\ more\\ sensitive\\ than\\ both\\ t2i\\ and\\ flair\\.\\ dwi\\ shows\\ symmetrical\\ high\\ intensity\\ lesions\\ in\\ the\\ striatum\\ \\(caudate\\ and\\ putamen\\)\\,\\ the\\ dorsomedial\\ thalamic\\ nuclei\\,\\ and\\ cerebral\\ cortical\\ lesions\\.\\ these\\ findings\\ were\\ identifiable\\ before\\ pswc\\â\\€\\™s\\ on\\ eeg\\ \\,\\ and\\ before\\ the\\ final\\ stages\\ of\\ the\\ disease\\,\\ which\\ results\\ in\\ brain\\ atrophy\\.\\ \\ \ \(0\)\
\-\ treatment\\ at\\ this\\ time\\ is\\ symptomatic\\ and\\ palliative\\,\\ but\\ a\\ number\\ of\\ experimental\\ interventions\\ are\\ being\\ tested\\,\\ such\\ as\\ antimalarial\\ quinacrine\\,\\ chlorpromazine\\,\\ and\\ pentosan\\ polysulphate\\,\\ which\\ prevent\\ prion\\ conversion\\ and\\ production\\,\\ and\\ an\\ immunization\\ that\\ reduces\\ the\\ cerebral\\ amyloid\\ accumulation\\.\\ \ \(0\)\
\-\ finally\\,\\ as\\ seen\\ with\\ this\\ patient\\,\\ cjd\\ must\\ always\\ be\\ in\\ a\\ differential\\ for\\ rapid\\ dementia\\ or\\ for\\ patients\\ experiencing\\ changes\\ in\\ mood\\,\\ ataxia\\,\\ and\\ visual\\ disturbances\\.\ \(0\)\
\-\ today\\,\\ we\\ can\\ only\\ ease\\ the\\ suffering\\ of\\ cjd\\,\\ but\\ on\\ the\\ horizon\\ a\\ treatment\\ may\\ be\\ near\\,\\ and\\ someday\\ we\\ can\\ offer\\ a\\ real\\ cure\\ and\\ a\\ way\\ to\\ stop\\ this\\ deadly\\ prion\\ disease\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cjd\\:\\ 0\\.0984003187132001\ \(0\)\
\-\ prion\\:\\ 0\\.02689526901790249\ \(0\)\
\-\ eeg\\:\\ 0\\.025920880550993633\ \(0\)\
\-\ familial\\:\\ 0\\.02309933547686706\ \(0\)\
\-\ dwi\\:\\ 0\\.020039083024063768\ \(0\)\
\-\ \\,\\:\\ 0\\.01972060079927259\ \(0\)\
\-\ respectfully\\:\\ 0\\.019460305571669976\ \(0\)\
\-\ dementia\\:\\ 0\\.01895521844572246\ \(0\)\
\-\ auto\\-antibodies\\:\\ 0\\.01793017934526833\ \(0\)\
\-\ 14\\-3\\-3\\:\\ 0\\.017035112881453394\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.01666002910611999\ \(0\)\
\-\ sensitivity\\:\\ 0\\.015981901911927894\ \(0\)\
\-\ hypometabolism\\:\\ 0\\.01550498665505175\ \(0\)\
\-\ mood\\:\\ 0\\.01550498665505175\ \(0\)\
\-\ proteins\\:\\ 0\\.015164698178611886\ \(0\)\
\-\ protein\\:\\ 0\\.014518879553388027\ \(0\)\
\-\ pt\\:\\ 0\\.014027213044736213\ \(0\)\
\-\ populations\\:\\ 0\\.013974860428650105\ \(0\)\
\-\ hashimoto\\:\\ 0\\.013634571952210241\ \(0\)\
\-\ ward\\:\\ 0\\.013205971478830646\ \(0\)\
\-\ visual\\:\\ 0\\.012827403978003953\ \(0\)\
\-\ started\\:\\ 0\\.012621099728546487\ \(0\)\
\-\ disease\\:\\ 0\\.012333223321992973\ \(0\)\
\-\ specificity\\:\\ 0\\.01226803948332233\ \(0\)\
\-\ amyloid\\:\\ 0\\.01218472750102024\ \(0\)\
\-\ sporadic\\:\\ 0\\.01218472750102024\ \(0\)\
\-\ mean\\:\\ 0\\.011741745833333372\ \(0\)\
\-\ a\\:\\ 0\\.011381451266317476\ \(0\)\
\-\ brain\\:\\ 0\\.011352545356745085\ \(0\)\
\-\ stages\\:\\ 0\\.011317083818659077\ \(0\)\
\-\ \\%\\:\\ 0\\.011000667954448167\ \(0\)\
\-\ changes\\:\\ 0\\.010812573846512408\ \(0\)\
\-\ abnormal\\:\\ 0\\.010759789140463185\ \(0\)\
\-\ he\\:\\ 0\\.010526213430609358\ \(0\)\
\-\ abnormalities\\:\\ 0\\.010393260336749062\ \(0\)\
\-\ cortical\\:\\ 0\\.010314817386012622\ \(0\)\
\-\ sensitive\\:\\ 0\\.010245322635918014\ \(0\)\
\-\ and\\:\\ 0\\.010132957276316933\ \(0\)\
\-\ ataxia\\:\\ 0\\.01008172887840428\ \(0\)\
\-\ dysfunction\\:\\ 0\\.010050416218377886\ \(0\)\
\-\ we\\:\\ 0\\.009929426733841475\ \(0\)\
\-\ pet\\:\\ 0\\.009900187822693526\ \(0\)\
\-\ polysegs\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ paraneoplastic\\/neoplastic\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ serroquel\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ lobe\\/post\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ lewey\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ conformation\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ self\\-perpetuating\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ internationally\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ libyan\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ rural\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ slovakia\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ imparement\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ behavorial\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ extrapyramidal\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ bed\\-ridden\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ pswcs\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ low\\-voltage\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ 50\\.0\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ 84\\.0\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ 73\\.3\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ t2i\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ striatum\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ pswc\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ quinacrine\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ chlorpromazine\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ pentosan\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ polysulphate\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ someday\\:\\ 0\\.009730152785834988\ \(0\)\
\-\ rapid\\:\\ 0\\.009526950891029213\ \(0\)\
\-\ cases\\:\\ 0\\.009426526039672624\ \(0\)\
\-\ testing\\:\\ 0\\.00912447504821695\ \(0\)\
\-\ variant\\:\\ 0\\.008985841712148451\ \(0\)\
\-\ geodon\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ sundowning\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ micu\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ lability\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ neurodegenerative\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ replicates\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ incubation\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ jerks\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ neuron\\-specific\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ enolase\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ 92\\.3\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ 93\\.8\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ dorsomedial\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ antimalarial\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ horizon\\:\\ 0\\.008965089672634164\ \(0\)\
\-\ form\\:\\ 0\\.00881950741360146\ \(0\)\
\-\ gait\\:\\ 0\\.008784186571777087\ \(0\)\
\-\ r\\:\\ 0\\.008567427132087873\ \(0\)\
\-\ protecting\\:\\ 0\\.008517556440726697\ \(0\)\
\-\ creutzfeldt\\-jacob\\:\\ 0\\.008517556440726697\ \(0\)\
\-\ transmissible\\:\\ 0\\.008517556440726697\ \(0\)\
\-\ spongiform\\:\\ 0\\.008517556440726697\ \(0\)\
\-\ glycoprotein\\:\\ 0\\.008517556440726697\ \(0\)\
\-\ jewish\\:\\ 0\\.008517556440726697\ \(0\)\
\-\ 60\\-100\\:\\ 0\\.008517556440726697\ \(0\)\
\-\ myoclonic\\:\\ 0\\.008517556440726697\ \(0\)\
\-\ deadly\\:\\ 0\\.008517556440726697\ \(0\)\
\-\ only\\:\\ 0\\.008507985624122303\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.008457042184256476\ \(0\)\
\-\ ast\\/alt\\:\\ 0\\.00820002655943334\ \(0\)\
\-\ 80mg\\:\\ 0\\.00820002655943334\ \(0\)\
\-\ multi\\-infarct\\:\\ 0\\.00820002655943334\ \(0\)\
\-\ bronchopneumonia\\:\\ 0\\.00820002655943334\ \(0\)\
\-\ ease\\:\\ 0\\.00820002655943334\ \(0\)\
\-\ offer\\:\\ 0\\.00820002655943334\ \(0\)\
\-\ that\\:\\ 0\\.00814558900970653\ \(0\)\
\-\ continued\\:\\ 0\\.008123002178623039\ \(0\)\
\-\ s\\:\\ 0\\.00811512472554499\ \(0\)\
\-\ is\\:\\ 0\\.008068189976822774\ \(0\)\
\-\ test\\:\\ 0\\.008059012030999966\ \(0\)\
\-\ for\\:\\ 0\\.008047551309522243\ \(0\)\
\-\ before\\:\\ 0\\.00798459468587345\ \(0\)\
\-\ bumps\\:\\ 0\\.007953731248932006\ \(0\)\
\-\ million\\:\\ 0\\.007953731248932006\ \(0\)\
\-\ sixty\\:\\ 0\\.007953731248932006\ \(0\)\
\-\ immunization\\:\\ 0\\.007953731248932006\ \(0\)\
\-\ reduces\\:\\ 0\\.007953731248932006\ \(0\)\
\-\ after\\:\\ 0\\.0078057448238816884\ \(0\)\
\-\ specific\\:\\ 0\\.007797604183727395\ \(0\)\
\-\ nhl\\:\\ 0\\.007752493327525875\ \(0\)\
\-\ thyroid\\:\\ 0\\.007731374050606425\ \(0\)\
\-\ months\\:\\ 0\\.007728282432748567\ \(0\)\
\-\ results\\:\\ 0\\.00761488390495507\ \(0\)\
\-\ macular\\:\\ 0\\.007582349089305943\ \(0\)\
\-\ transitioned\\:\\ 0\\.007582349089305943\ \(0\)\
\-\ cerebrum\\:\\ 0\\.007582349089305943\ \(0\)\
\-\ experimental\\:\\ 0\\.007582349089305943\ \(0\)\
\-\ temporal\\:\\ 0\\.007553842996940699\ \(0\)\
\-\ progressive\\:\\ 0\\.0074557154857468055\ \(0\)\
\-\ dysmetria\\:\\ 0\\.007434963446232519\ \(0\)\
\-\ agitation\\:\\ 0\\.007434963446232519\ \(0\)\
\-\ creutzfeldt\\-jakob\\:\\ 0\\.007434963446232519\ \(0\)\
\-\ alzheimer\\:\\ 0\\.007434963446232519\ \(0\)\
\-\ classifications\\:\\ 0\\.007434963446232519\ \(0\)\
\-\ steadily\\:\\ 0\\.007434963446232519\ \(0\)\
\-\ complexes\\:\\ 0\\.007434963446232519\ \(0\)\
\-\ homonymous\\:\\ 0\\.007304960095618409\ \(0\)\
\-\ bilat\\:\\ 0\\.007304960095618409\ \(0\)\
\-\ extubated\\:\\ 0\\.007304960095618409\ \(0\)\
\-\ tandem\\:\\ 0\\.007188668135731184\ \(0\)\
\-\ personality\\:\\ 0\\.007188668135731184\ \(0\)\
\-\ host\\:\\ 0\\.007188668135731184\ \(0\)\
\-\ pyramidal\\:\\ 0\\.007188668135731184\ \(0\)\
\-\ as\\:\\ 0\\.007133429944228079\ \(0\)\
\-\ course\\:\\ 0\\.007118170956855721\ \(0\)\
\-\ has\\:\\ 0\\.007084768081652441\ \(0\)\
\-\ romberg\\:\\ 0\\.007083469261774975\ \(0\)\
\-\ conversion\\:\\ 0\\.007083469261774975\ \(0\)\
\-\ cure\\:\\ 0\\.007083469261774975\ \(0\)\
\-\ to\\:\\ 0\\.007070664047069309\ \(0\)\
\-\ which\\:\\ 0\\.0070425809591282505\ \(0\)\
\-\ objects\\:\\ 0\\.006987430214325053\ \(0\)\
\-\ suffering\\:\\ 0\\.006987430214325053\ \(0\)\
\-\ dtrs\\:\\ 0\\.006899082854861988\ \(0\)\
\-\ worsen\\:\\ 0\\.006899082854861988\ \(0\)\
\-\ inherited\\:\\ 0\\.006899082854861988\ \(0\)\
\-\ moved\\:\\ 0\\.0068172859761051205\ \(0\)\
\-\ hsv\\:\\ 0\\.0068172859761051205\ \(0\)\
\-\ putamen\\:\\ 0\\.0068172859761051205\ \(0\)\
\-\ they\\:\\ 0\\.0067967905661971435\ \(0\)\
\-\ rbcs\\:\\ 0\\.0067411349038237174\ \(0\)\
\-\ seventh\\:\\ 0\\.0067411349038237174\ \(0\)\
\-\ biopsy\\:\\ 0\\.006692479562112054\ \(0\)\
\-\ ventilator\\:\\ 0\\.006669900333031696\ \(0\)\
\-\ signs\\:\\ 0\\.006638798971271643\ \(0\)\
\-\ lp\\:\\ 0\\.006602985739415323\ \(0\)\
\-\ being\\:\\ 0\\.006573483392495714\ \(0\)\
\-\ was\\:\\ 0\\.0065448842530707735\ \(0\)\
\-\ coordination\\:\\ 0\\.006539896982417587\ \(0\)\
\-\ wave\\:\\ 0\\.006539896982417587\ \(0\)\
\-\ supports\\:\\ 0\\.006539896982417587\ \(0\)\
\-\ thalamic\\:\\ 0\\.006539896982417587\ \(0\)\
\-\ cerebral\\:\\ 0\\.006535201990649163\ \(0\)\
\-\ ranging\\:\\ 0\\.006480220137748408\ \(0\)\
\-\ can\\:\\ 0\\.006417954809500231\ \(0\)\
\-\ elevated\\:\\ 0\\.006400256868342303\ \(0\)\
\-\ on\\:\\ 0\\.006391973619120778\ \(0\)\
\-\ present\\:\\ 0\\.006390757463349936\ \(0\)\
\-\ fatal\\:\\ 0\\.006369752744197654\ \(0\)\
\-\ identifiable\\:\\ 0\\.006369752744197654\ \(0\)\
\-\ three\\:\\ 0\\.006358993881560509\ \(0\)\
\-\ hemianopsia\\:\\ 0\\.0063184061485741525\ \(0\)\
\-\ decline\\:\\ 0\\.0063184061485741525\ \(0\)\
\-\ expired\\:\\ 0\\.0063184061485741525\ \(0\)\
\-\ improving\\:\\ 0\\.0063184061485741525\ \(0\)\
\-\ caudate\\:\\ 0\\.0063184061485741525\ \(0\)\
\-\ cognitive\\:\\ 0\\.006269342392977206\ \(0\)\
\-\ interventions\\:\\ 0\\.006269342392977206\ \(0\)\
\-\ tested\\:\\ 0\\.006269342392977206\ \(0\)\
\-\ stop\\:\\ 0\\.006269342392977206\ \(0\)\
\-\ qd\\:\\ 0\\.00622236710112423\ \(0\)\
\-\ sixth\\:\\ 0\\.00622236710112423\ \(0\)\
\-\ classified\\:\\ 0\\.006177309712029026\ \(0\)\
\-\ cycle\\:\\ 0\\.006177309712029026\ \(0\)\
\-\ background\\:\\ 0\\.006177309712029026\ \(0\)\
\-\ disturbances\\:\\ 0\\.006177309712029026\ \(0\)\
\-\ today\\:\\ 0\\.006177309712029026\ \(0\)\
\-\ real\\:\\ 0\\.006177309712029026\ \(0\)\
\-\ symmetrical\\:\\ 0\\.00609236375051012\ \(0\)\
\-\ but\\:\\ 0\\.006034779142495158\ \(0\)\
\-\ decreasing\\:\\ 0\\.006013490721832256\ \(0\)\
\-\ mutation\\:\\ 0\\.006013490721832256\ \(0\)\
\-\ periodic\\:\\ 0\\.006013490721832256\ \(0\)\
\-\ regional\\:\\ 0\\.005976071790622895\ \(0\)\
\-\ onset\\:\\ 0\\.005954572242660375\ \(0\)\
\-\ nystagmus\\:\\ 0\\.005939879933202375\ \(0\)\
\-\ acuity\\:\\ 0\\.005939879933202375\ \(0\)\
\-\ accounts\\:\\ 0\\.005939879933202375\ \(0\)\
\-\ nuclei\\:\\ 0\\.005904837219830874\ \(0\)\
\-\ such\\:\\ 0\\.005896981876028371\ \(0\)\
\-\ disability\\:\\ 0\\.005870872916666686\ \(0\)\
\-\ united\\:\\ 0\\.005805927552402963\ \(0\)\
\-\ experiencing\\:\\ 0\\.005805927552402963\ \(0\)\
\-\ show\\:\\ 0\\.0057906312019682694\ \(0\)\
\-\ scanning\\:\\ 0\\.005774833869216765\ \(0\)\
\-\ horizontal\\:\\ 0\\.005744592175852399\ \(0\)\
\-\ neurology\\:\\ 0\\.005744592175852399\ \(0\)\
\-\ 83\\:\\ 0\\.005744592175852399\ \(0\)\
\-\ palliative\\:\\ 0\\.005744592175852399\ \(0\)\
\-\ treatment\\:\\ 0\\.005727208475499626\ \(0\)\
\-\ production\\:\\ 0\\.0057151570245475855\ \(0\)\
\-\ finally\\:\\ 0\\.0057151570245475855\ \(0\)\
\-\ accomplished\\:\\ 0\\.005658541909329538\ \(0\)\
\-\ sparing\\:\\ 0\\.0056046896309968315\ \(0\)\
\-\ intubated\\:\\ 0\\.0056046896309968315\ \(0\)\
\-\ in\\:\\ 0\\.005581420266758344\ \(0\)\
\-\ prednisone\\:\\ 0\\.005578717779550701\ \(0\)\
\-\ diagnoses\\:\\ 0\\.005578717779550701\ \(0\)\
\-\ decade\\:\\ 0\\.00555334303537333\ \(0\)\
\-\ years\\:\\ 0\\.005539168072888482\ \(0\)\
\-\ vertical\\:\\ 0\\.005528538558715429\ \(0\)\
\-\ way\\:\\ 0\\.005528538558715429\ \(0\)\
\-\ ultimately\\:\\ 0\\.005504279279776383\ \(0\)\
\-\ autosomal\\:\\ 0\\.005457303987923408\ \(0\)\
\-\ bleed\\:\\ 0\\.005390389394307033\ \(0\)\
\-\ effective\\:\\ 0\\.005368956628460342\ \(0\)\
\-\ time\\:\\ 0\\.0053280380292258555\ \(0\)\
\-\ work\\-up\\:\\ 0\\.0053273006373092974\ \(0\)\
\-\ w\\/o\\:\\ 0\\.0053273006373092974\ \(0\)\
\-\ state\\:\\ 0\\.0053273006373092974\ \(0\)\
\-\ consultation\\:\\ 0\\.005267623792640119\ \(0\)\
\-\ encephalitis\\:\\ 0\\.005267623792640119\ \(0\)\
\-\ plaques\\:\\ 0\\.005267623792640119\ \(0\)\
\-\ occurring\\:\\ 0\\.005267623792640119\ \(0\)\
\-\ airway\\:\\ 0\\.005248427608631434\ \(0\)\
\-\ etiologies\\:\\ 0\\.005229559580641036\ \(0\)\
\-\ hiv\\:\\ 0\\.005229559580641036\ \(0\)\
\-\ 63\\:\\ 0\\.005229559580641036\ \(0\)\
\-\ rapidly\\:\\ 0\\.005229559580641036\ \(0\)\
\-\ high\\:\\ 0\\.00516235333571041\ \(0\)\
\-\ 62\\:\\ 0\\.005157156399089366\ \(0\)\
\-\ percent\\:\\ 0\\.005139774106630051\ \(0\)\
\-\ excluded\\:\\ 0\\.0051058098034658635\ \(0\)\
\-\ processes\\:\\ 0\\.0051058098034658635\ \(0\)\
\-\ sharp\\:\\ 0\\.0051058098034658635\ \(0\)\
\-\ slow\\:\\ 0\\.0051058098034658635\ \(0\)\
\-\ death\\:\\ 0\\.005089211704829506\ \(0\)\
\-\ final\\:\\ 0\\.005089211704829506\ \(0\)\
\-\ transferred\\:\\ 0\\.005072859513013677\ \(0\)\
\-\ lesions\\:\\ 0\\.00504980244226037\ \(0\)\
\-\ glucose\\:\\ 0\\.00504086443920214\ \(0\)\
\-\ due\\:\\ 0\\.005033724399454392\ \(0\)\
\-\ retroperitoneal\\:\\ 0\\.005025208109188943\ \(0\)\
\-\ accumulation\\:\\ 0\\.005025208109188943\ \(0\)\
\-\ duration\\:\\ 0\\.0049945463386513326\ \(0\)\
\-\ primarily\\:\\ 0\\.004950093911346763\ \(0\)\
\-\ than\\:\\ 0\\.00494271270401385\ \(0\)\
\-\ dose\\:\\ 0\\.004935665565245932\ \(0\)\
\-\ these\\:\\ 0\\.004909149430370508\ \(0\)\
\-\ patients\\:\\ 0\\.004882063133258335\ \(0\)\
\-\ atrophy\\:\\ 0\\.004866224256845745\ \(0\)\
\-\ am\\:\\ 0\\.004852845271710707\ \(0\)\
\-\ always\\:\\ 0\\.004852845271710707\ \(0\)\
\-\ dominant\\:\\ 0\\.004813654666349879\ \(0\)\
\-\ corresponding\\:\\ 0\\.004800894376723968\ \(0\)\
\-\ \\(\\:\\ 0\\.004783852491681196\ \(0\)\
\-\ date\\:\\ 0\\.004739216166575561\ \(0\)\
\-\ \\)\\:\\ 0\\.004725415179558312\ \(0\)\
\-\ more\\:\\ 0\\.00471782849737785\ \(0\)\
\-\ alert\\:\\ 0\\.004703798600845428\ \(0\)\
\-\ number\\:\\ 0\\.004703798600845428\ \(0\)\
\-\ symptoms\\:\\ 0\\.004701230633329226\ \(0\)\
\-\ progression\\:\\ 0\\.0046922408747225855\ \(0\)\
\-\ cerebellum\\:\\ 0\\.0046922408747225855\ \(0\)\
\-\ characterized\\:\\ 0\\.0046922408747225855\ \(0\)\
\-\ overall\\:\\ 0\\.0046922408747225855\ \(0\)\
\-\ prevent\\:\\ 0\\.004680802919937214\ \(0\)\
\-\ different\\:\\ 0\\.0046694822795760775\ \(0\)\
\-\ metabolic\\:\\ 0\\.004658276571558398\ \(0\)\
\-\ definitive\\:\\ 0\\.004658276571558398\ \(0\)\
\-\ oriented\\:\\ 0\\.00462532628110621\ \(0\)\
\-\ higher\\:\\ 0\\.00462532628110621\ \(0\)\
\-\ increased\\:\\ 0\\.004614756692714472\ \(0\)\
\-\ 17\\:\\ 0\\.0045933312072946745\ \(0\)\
\-\ times\\:\\ 0\\.004572505065678357\ \(0\)\
\-\ disorders\\:\\ 0\\.004512285436262867\ \(0\)\
\-\ medicine\\:\\ 0\\.0044738901646454105\ \(0\)\
\-\ steroids\\:\\ 0\\.004436785737714963\ \(0\)\
\-\ states\\:\\ 0\\.004436785737714963\ \(0\)\
\-\ period\\:\\ 0\\.00440975370680073\ \(0\)\
\-\ mental\\:\\ 0\\.004400888175126045\ \(0\)\
\-\ occipital\\:\\ 0\\.004400888175126045\ \(0\)\
\-\ spontaneous\\:\\ 0\\.004400888175126045\ \(0\)\
\-\ though\\:\\ 0\\.004374710993429228\ \(0\)\
\-\ 26\\:\\ 0\\.004366121434442412\ \(0\)\
\-\ like\\:\\ 0\\.004366121434442412\ \(0\)\
\-\ unable\\:\\ 0\\.004357598204758185\ \(0\)\
\-\ most\\:\\ 0\\.004355044462975886\ \(0\)\
\-\ having\\:\\ 0\\.004332416441219365\ \(0\)\
\-\ incidence\\:\\ 0\\.0043241485916286826\ \(0\)\
\-\ flair\\:\\ 0\\.0043241485916286826\ \(0\)\
\-\ must\\:\\ 0\\.0042997102628458865\ \(0\)\
\-\ were\\:\\ 0\\.004283192796224992\ \(0\)\
\-\ 16\\:\\ 0\\.004267945401311622\ \(0\)\
\-\ poor\\:\\ 0\\.004244707642815119\ \(0\)\
\-\ few\\:\\ 0\\.004244707642815119\ \(0\)\
\-\ this\\:\\ 0\\.004243431405360411\ \(0\)\
\-\ diffusion\\:\\ 0\\.004221949047668611\ \(0\)\
\-\ difficulty\\:\\ 0\\.004199650253719914\ \(0\)\
\-\ even\\:\\ 0\\.004199650253719914\ \(0\)\
\-\ worse\\:\\ 0\\.004177793049198745\ \(0\)\
\-\ may\\:\\ 0\\.004137590218318154\ \(0\)\
\-\ per\\:\\ 0\\.004128415682927893\ \(0\)\
\-\ difficult\\:\\ 0\\.004128415682927893\ \(0\)\
\-\ life\\:\\ 0\\.004114704292201009\ \(0\)\
\-\ weighted\\:\\ 0\\.004101161143644922\ \(0\)\
\-\ do\\:\\ 0\\.0040944513797637055\ \(0\)\
\-\ have\\:\\ 0\\.004084852270121615\ \(0\)\
\-\ neurological\\:\\ 0\\.0040811529928805115\ \(0\)\
\-\ near\\:\\ 0\\.0040811529928805115\ \(0\)\
\-\ admitted\\:\\ 0\\.004074563404595187\ \(0\)\
\-\ full\\:\\ 0\\.004074563404595187\ \(0\)\
\-\ cerebellar\\:\\ 0\\.00406801292388899\ \(0\)\
\-\ hydrocephalus\\:\\ 0\\.00405502744753183\ \(0\)\
\-\ infectious\\:\\ 0\\.00405502744753183\ \(0\)\
\-\ cortex\\:\\ 0\\.004035831263523144\ \(0\)\
\-\ characteristic\\:\\ 0\\.003992297342936725\ \(0\)\
\-\ general\\:\\ 0\\.003974153053374738\ \(0\)\
\-\ best\\:\\ 0\\.003968170638949419\ \(0\)\
\-\ increase\\:\\ 0\\.003956302215355311\ \(0\)\
\-\ arm\\:\\ 0\\.003950415520018266\ \(0\)\
\-\ condition\\:\\ 0\\.003944560053981077\ \(0\)\
\-\ an\\:\\ 0\\.003912797563856722\ \(0\)\
\-\ many\\:\\ 0\\.003876615359721217\ \(0\)\
\-\ family\\:\\ 0\\.0038656870253032127\ \(0\)\
\-\ are\\:\\ 0\\.003857198253409277\ \(0\)\
\-\ presenting\\:\\ 0\\.003844149702760628\ \(0\)\
\-\ at\\:\\ 0\\.0038336528239458047\ \(0\)\
\-\ placed\\:\\ 0\\.0038178059042985493\ \(0\)\
\-\ reports\\:\\ 0\\.003802296242647721\ \(0\)\
\-\ symptomatic\\:\\ 0\\.0037472223230620443\ \(0\)\
\-\ \\:\\:\\ 0\\.003742631841028692\ \(0\)\
\-\ rate\\:\\ 0\\.0036762930358453013\ \(0\)\
\-\ about\\:\\ 0\\.003635825061925223\ \(0\)\
\-\ result\\:\\ 0\\.003618304808993335\ \(0\)\
\-\ pattern\\:\\ 0\\.003605344745111786\ \(0\)\
\-\ its\\:\\ 0\\.0035590854784278603\ \(0\)\
\-\ confirmed\\:\\ 0\\.00354679867890375\ \(0\)\
\-\ 8\\:\\ 0\\.0035266198214672717\ \(0\)\
\-\ of\\:\\ 0\\.003471967573449986\ \(0\)\
\-\ extremity\\:\\ 0\\.003449402836249931\ \(0\)\
\-\ early\\:\\ 0\\.003449402836249931\ \(0\)\
\-\ intensity\\:\\ 0\\.003409128781875608\ \(0\)\
\-\ status\\:\\ 0\\.0033668071977722446\ \(0\)\
\-\ the\\:\\ 0\\.0033570466484324143\ \(0\)\
\-\ new\\:\\ 0\\.003286741696247857\ \(0\)\
\-\ labs\\:\\ 0\\.003280324510965936\ \(0\)\
\-\ long\\:\\ 0\\.0032519001223319244\ \(0\)\
\-\ 3\\.\\:\\ 0\\.003227234229735902\ \(0\)\
\-\ week\\:\\ 0\\.0032031075257485963\ \(0\)\
\-\ 10\\:\\ 0\\.0031794969407802545\ \(0\)\
\-\ possible\\:\\ 0\\.0031765808155453336\ \(0\)\
\-\ areas\\:\\ 0\\.003173672374443782\ \(0\)\
\-\ left\\:\\ 0\\.0031659114876586582\ \(0\)\
\-\ x\\:\\ 0\\.0031115522465203944\ \(0\)\
\-\ showed\\:\\ 0\\.003092498088216001\ \(0\)\
\-\ body\\:\\ 0\\.003063204980893029\ \(0\)\
\-\ positive\\:\\ 0\\.0030605801217263983\ \(0\)\
\-\ day\\:\\ 0\\.0029944368977405404\ \(0\)\
\-\ differential\\:\\ 0\\.0029944368977405404\ \(0\)\
\-\ found\\:\\ 0\\.0029724344530376516\ \(0\)\
\-\ frontal\\:\\ 0\\.0029627946296725796\ \(0\)\
\-\ approximately\\:\\ 0\\.002918121221363778\ \(0\)\
\-\ be\\:\\ 0\\.0029089552391698215\ \(0\)\
\-\ severe\\:\\ 0\\.00290210794709272\ \(0\)\
\-\ during\\:\\ 0\\.0028863236754125914\ \(0\)\
\-\ age\\:\\ 0\\.0028707619487244\ \(0\)\
\-\ some\\:\\ 0\\.0028641592206034867\ \(0\)\
\-\ diffuse\\:\\ 0\\.002855416578780701\ \(0\)\
\-\ following\\:\\ 0\\.0026769070164471835\ \(0\)\
\-\ weeks\\:\\ 0\\.0026769070164471835\ \(0\)\
\-\ t2\\:\\ 0\\.002669524027318269\ \(0\)\
\-\ all\\:\\ 0\\.0026676859706747137\ \(0\)\
\-\ secondary\\:\\ 0\\.0026368984177801407\ \(0\)\
\-\ however\\:\\ 0\\.0026262340569504087\ \(0\)\
\-\ low\\:\\ 0\\.0026227020451064014\ \(0\)\
\-\ y\\/o\\:\\ 0\\.0026121733220967336\ \(0\)\
\-\ shows\\:\\ 0\\.0025931277038950097\ \(0\)\
\-\ both\\:\\ 0\\.0024086092612429595\ \(0\)\
\-\ upper\\:\\ 0\\.0022760270478683424\ \(0\)\
\-\ into\\:\\ 0\\.0022442895893595\ \(0\)\
\-\ 1\\:\\ 0\\.0022442895893595\ \(0\)\
\-\ tissue\\:\\ 0\\.0022355642256651144\ \(0\)\
\-\ or\\:\\ 0\\.002210866995504873\ \(0\)\
\-\ mri\\:\\ 0\\.0021669711422898676\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0021658050008613906\ \(0\)\
\-\ it\\:\\ 0\\.002120141704782579\ \(0\)\
\-\ case\\:\\ 0\\.002063470676453941\ \(0\)\
\-\ had\\:\\ 0\\.0020351543258727463\ \(0\)\
\-\ findings\\:\\ 0\\.002007546286743885\ \(0\)\
\-\ right\\:\\ 0\\.0019903569737536792\ \(0\)\
\-\ seen\\:\\ 0\\.0018638273896994374\ \(0\)\
\-\ also\\:\\ 0\\.0018594035250222422\ \(0\)\
\-\ images\\:\\ 0\\.0018093420440942099\ \(0\)\
\-\ male\\:\\ 0\\.001705524876255489\ \(0\)\
\-\ by\\:\\ 0\\.0015704976857007448\ \(0\)\
\-\ \\.\\:\\ 0\\.0015673084369689306\ \(0\)\
\-\ normal\\:\\ 0\\.0014786009432661159\ \(0\)\
\-\ with\\:\\ 0\\.0014205805044026347\ \(0\)\
\-\ there\\:\\ 0\\.0014036595545971178\ \(0\)\
\-\ from\\:\\ 0\\.0013978319129737443\ \(0\)\
\-\ history\\:\\ 0\\.001302665052656825\ \(0\)\
\-\ no\\:\\ 0\\.0009497176056333356\ \(0\)\
\-\ patient\\:\\ 0\\.0009454657074132318\ \(0\)\
